Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

Effectiveness of Low -Versus High -Volume High -Intensity Interval Training in Patients With Chronic Heart Failure

NCT07325942 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2025-12-10
Last updated
2026-01-08

Condition(s) studied

Chronic Heart Failure

Investigational drug(s) / intervention(s)

low-volume high intensity interval trainingHigh volume high intensity interval trainingStandard medical treatment

low-volume high intensity interval training: Low-volume HIIT (LV-HIIT) is a particularly time-efficient subtype of interval training, which has gained increasing attention in recent years. As per the previous definition, these brief training protocols typically involve≤10 min of intense exercise within a session lasting≤30 min including warm-up, recovery phases between intervals, and cool-down

High volume high intensity interval training: long (2-4 min) bouts of high (not maximum) intensity exercise interspersed with recovery periods which have wide varieties in the protocols according to the intensity, duration, and number of intervals performed

Standard medical treatment: standard medical treatment for chronic heart failure as per international guidlines

Study summary

this study aims to investigate the effect of low vs high volume- high intensity interval training on functional capacity and quality of life in chronic heart failure patients

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Chronic stable heart failure patient with reduced ejection fraction (EF \<40) 2. Age Above 18 years old 3. Both males and females 4. The ability to provide informed consent Exclusion Criteria: 1. Based on the Scientific Statement from the American Heart Association: contraindications for exercise Testing and Training. (Fletcher et al., 2013) 1. Acute myocardial infarction (MI), within 2 days 2. Ongoing unstable angina 3. Uncontrolled cardiac tachy or brady arrhythmia with hemodynamic compromise 4. Active endocarditis 5. Symptomatic severe aortic stenosis 6. Decompensated heart failure 7. Acute pulmonary embolism, pulmonary infarction, or deep vein thrombosis 8. Acute myocarditis or pericarditis 9. Acute aortic dissection 10. Physical disability that precludes safe and adequate testing or training 11. Known obstructive left main coronary artery stenosis 12. Hypertrophic obstructive cardiomyopathy with severe resting gradient 13. Recent stroke or transient ischemic attack 14. Mental impairment with limited ability to cooperate 15. Resting hypertension with systolic or diastolic blood pressures \>200/110 mmHg 16. Uncorrected medical conditions, such as significant anemia, important electrolyte imbalance, and hyperthyroidism 2. Acute decompensated heart failure NYHA class IV

Primary outcome measure(s)

  • 6 minute walk test — at enrolment and at the end of treatment at 8 weeks
    self-paced submaximal field exercise test to assess submaximal functional capacity of the patient , the distance walked by the patient for six minutes will be measured by meters
  • 2D Echocardiographic parameters — at enrollment and at the end of treatment at 8 weeks
    Left ventricle geometry: left ventricular end-diastolic diameter (LVEDD) mm, left ventricular end-systolic diameter (LVESD) mm, left ventricular end-systolic volume (LVESV) ml. and, left ventricular end-diastolic volume (LVEDV) ml. Left ventricle Systolic function: left ventricular ejection fraction (LVEF) % Left ventricle Diastolic function :E wave cm/s: early diastolic mitral inflow velocity, A wave cm/s: diastolic mitral inflow velocity during late atrial contraction , E/A ratio

Trial sites (1)

FacilityCityRegionStatus
Cairo University Cairo Giza Governorate Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07325942 on ClinicalTrials.gov ↗ ← All trials in Egypt